carbamazepine has been researched along with Psychomotor Agitation in 29 studies
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
Psychomotor Agitation: A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of oxcarbazepine (OXC) in the treatment of agitation and aggression in patients with Alzheimer's disease, vascular dementia or both." | 9.14 | Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia. ( Aga, O; Cvancarova, M; Engedal, K; Olsen, IC; Selbaek, G; Sommer, OH, 2009) |
| "The aim of this study was to assess the effects of withdrawal from placebo and carbamazepine administered for agitation associated with dementia and to assess safety, tolerability, and efficacy of subsequent ongoing carbamazepine therapy." | 9.09 | Withdrawal from controlled carbamazepine therapy followed by further carbamazepine treatment in patients with dementia. ( Cox, C; Erb, R; Irvine, C; Jakimovich, LJ; Lanning, B; Podgorski, CA; Tariot, PN, 1999) |
| "The efficacy, safety, and tolerability of carbamazepine in the treatment of agitation and aggression associated with dementia were assessed." | 9.08 | Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. ( Cox, C; Erb, R; Irvine, C; Jakimovich, L; Patel, S; Podgorski, CA; Tariot, PN, 1998) |
| "To determine the effects of carbamazepine versus placebo on ratings of behavior in agitated nursing home patients with dementia." | 9.07 | Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. ( Asnis, J; Cox, C; Erb, R; Irvine, C; Kolassa, J; Leibovici, A; Podgorski, CA; Tariot, PN, 1994) |
| " Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation." | 8.98 | Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Ahmed, U; Hussein, M; Miramontes, K; Ostinelli, EG; Rehman, FU, 2018) |
| "Treatment with carbamazepine was evaluated in an open study design in 29 gerontopsychiatric inpatients." | 5.29 | [Therapeutic use of carbamazepine for treatment of agitation and affective disorders in geriatric psychiatry patients]. ( Lemke, MR; Stuhlmann, W, 1994) |
| "To evaluate the efficacy of oxcarbazepine (OXC) in the treatment of agitation and aggression in patients with Alzheimer's disease, vascular dementia or both." | 5.14 | Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia. ( Aga, O; Cvancarova, M; Engedal, K; Olsen, IC; Selbaek, G; Sommer, OH, 2009) |
| "The aim of this study was to assess the effects of withdrawal from placebo and carbamazepine administered for agitation associated with dementia and to assess safety, tolerability, and efficacy of subsequent ongoing carbamazepine therapy." | 5.09 | Withdrawal from controlled carbamazepine therapy followed by further carbamazepine treatment in patients with dementia. ( Cox, C; Erb, R; Irvine, C; Jakimovich, LJ; Lanning, B; Podgorski, CA; Tariot, PN, 1999) |
| "The efficacy, safety, and tolerability of carbamazepine in the treatment of agitation and aggression associated with dementia were assessed." | 5.08 | Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. ( Cox, C; Erb, R; Irvine, C; Jakimovich, L; Patel, S; Podgorski, CA; Tariot, PN, 1998) |
| "To determine the effects of carbamazepine versus placebo on ratings of behavior in agitated nursing home patients with dementia." | 5.07 | Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. ( Asnis, J; Cox, C; Erb, R; Irvine, C; Kolassa, J; Leibovici, A; Podgorski, CA; Tariot, PN, 1994) |
| " Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation." | 4.98 | Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Ahmed, U; Hussein, M; Miramontes, K; Ostinelli, EG; Rehman, FU, 2018) |
| " The purpose of this review of the literature is to assess the interest and the limits of anticonvulsant mood stabilizers (carbamazepine, valproic acid, gabapentin, lamotrigine, topiramate, oxcarbazepine) in the treatment of the so-called "noncognitive" symptoms of dementia." | 4.84 | [Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD)]. ( Pinheiro, D, 2008) |
| " Lower doses of valproate and carbamazepine were required to prevent hyperactivity compared to doses required to block tonic-clonic seizures induced by pentylenetetrazole." | 3.73 | Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. ( Arban, R; Brackenborough, K; Gerrard, P; Large, C; Maraia, G; Wilson, A; Winyard, L, 2005) |
| "Carbamazepine has been reported to decrease agitation associated with various psychiatric disorders and to reduce neuroleptic side effects." | 2.68 | Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. ( Lemke, MR, 1995) |
| " Carbamazepine at a dosage of 800 mg daily was the most effective medication used." | 1.33 | Auditory hallucinations after right temporal gyri resection. ( Brennan, DM; Stewart, B, 2005) |
| "The woman experienced ataxia and agitation while receiving quetiapine, which resolved after carbamazepine was switched to oxcarbazepine." | 1.31 | Elevation of carbamazepine-10,11-epoxide by quetiapine. ( Fitzgerald, BJ; Okos, AJ, 2002) |
| "Treatment with carbamazepine was evaluated in an open study design in 29 gerontopsychiatric inpatients." | 1.29 | [Therapeutic use of carbamazepine for treatment of agitation and affective disorders in geriatric psychiatry patients]. ( Lemke, MR; Stuhlmann, W, 1994) |
| "Carbamazepine was used to treat two patients with paroxysmal behavioral episodes and preexisting psychiatric disease." | 1.27 | Is carbamazepine helpful in paroxysmal behavior disorders? ( Garbutt, JC; Loosen, PT, 1983) |
| "Carbamazepine treatment was effective in all patients." | 1.26 | Hypnogenic paroxysmal dystonia: epileptic seizure or a new syndrome? ( Cirignotta, F; Lugaresi, E, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (17.24) | 18.7374 |
| 1990's | 10 (34.48) | 18.2507 |
| 2000's | 11 (37.93) | 29.6817 |
| 2010's | 3 (10.34) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ostinelli, EG | 1 |
| Hussein, M | 1 |
| Ahmed, U | 1 |
| Rehman, FU | 1 |
| Miramontes, K | 1 |
| Adams, CE | 1 |
| Pinheiro, D | 1 |
| Sommer, OH | 1 |
| Aga, O | 1 |
| Cvancarova, M | 1 |
| Olsen, IC | 1 |
| Selbaek, G | 1 |
| Engedal, K | 1 |
| Waters, E | 1 |
| Morrall, MC | 1 |
| Murdoch-Eaton, D | 1 |
| Douglas, JF | 1 |
| Sanders, KB | 1 |
| Benneyworth, MH | 1 |
| Smith, JL | 1 |
| Dejean, VM | 1 |
| McGrew, SG | 1 |
| Veenstra-Vanderweele, J | 1 |
| Fitzgerald, BJ | 1 |
| Okos, AJ | 1 |
| Richard, I | 1 |
| Perrouin-Verbe, B | 1 |
| Rome, J | 1 |
| Bernat, C | 1 |
| Mathé, JF | 1 |
| Ogihara, T | 1 |
| Takahashi, T | 1 |
| Hanihara, T | 1 |
| Amano, N | 1 |
| Matsumoto, K | 1 |
| Heveling, T | 1 |
| Emrich, HM | 1 |
| Dietrich, DE | 1 |
| Cummings, MR | 1 |
| Miller, BD | 1 |
| Arban, R | 1 |
| Maraia, G | 1 |
| Brackenborough, K | 1 |
| Winyard, L | 1 |
| Wilson, A | 1 |
| Gerrard, P | 1 |
| Large, C | 1 |
| Stewart, B | 1 |
| Brennan, DM | 1 |
| Nagata, T | 1 |
| Harada, D | 1 |
| Aoki, K | 1 |
| Kada, H | 1 |
| Miyata, H | 1 |
| Kasahara, H | 1 |
| Nakayama, K | 1 |
| Kolstee, HJ | 1 |
| Garbutt, JC | 1 |
| Loosen, PT | 1 |
| Lugaresi, E | 1 |
| Cirignotta, F | 1 |
| Lemke, MR | 2 |
| Stuhlmann, W | 1 |
| Tariot, PN | 3 |
| Erb, R | 3 |
| Leibovici, A | 1 |
| Podgorski, CA | 3 |
| Cox, C | 3 |
| Asnis, J | 1 |
| Kolassa, J | 1 |
| Irvine, C | 3 |
| Zayas, EM | 1 |
| Grossberg, GT | 1 |
| Mintzer, JE | 1 |
| Brawman-Mintzer, O | 1 |
| Patel, S | 1 |
| Jakimovich, L | 1 |
| Jakimovich, LJ | 1 |
| Lanning, B | 1 |
| Azouvi, P | 1 |
| Jokic, C | 1 |
| Attal, N | 1 |
| Denys, P | 1 |
| Markabi, S | 1 |
| Bussel, B | 1 |
| Olin, JT | 1 |
| Fox, LS | 1 |
| Pawluczyk, S | 1 |
| Taggart, NA | 1 |
| Schneider, LS | 2 |
| Signer, SF | 1 |
| Gleason, RP | 1 |
| Marin, DB | 1 |
| Greenwald, BS | 1 |
| Deutsch, SI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD) - An Eight Week Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi Center Trial. A Phase III Study[NCT00145691] | Phase 3 | 100 participants | Interventional | 2005-09-30 | Completed | ||
| Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression: A 42-Day, Single-Site, Forced-Titration, Parallel Group, Randomized, Double-Blind, Placebo Controlled Trial[NCT00621751] | 70 participants (Actual) | Interventional | 2008-02-29 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Study physician's impression of change since study onset. Clinicians Global Impressions of Change (CGI) is a sensitive, standardized tool to assess psychopharmacologic treatment response completed by the study physician. The Global Improvement (GI) CGI subscale documented the clinician's impression of change. The GI uses a 7-point scale to assess beneficial and negative effects. Low GI values (1 -3) indicate improvement; higher values (4-7) represent worsening. (NCT00621751)
Timeframe: 42 days
| Intervention | units on a scale (Mean) |
|---|---|
| Carbamazepine | 3.1 |
| Placebo | 2.9 |
Global Impression of Change (GIC) is a 5-item Likert Scale rated participants and observer impression of change in the person with TBI. Responses range 1 = much improved to 5 = much worse. (NCT00621751)
Timeframe: 42 days
| Intervention | units on a scale (Mean) |
|---|---|
| Carbamazepine | 3.3 |
| Placebo | 3.1 |
Global Impression of Change (GIC) is a 5-item Likert Scale rated participants and observer impression of change in the person with TBI. Responses range 1 = much improved to 5 = much worse. (NCT00621751)
Timeframe: Day-42
| Intervention | score on a scale (Mean) |
|---|---|
| Carbamazepine | 3.1 |
| Placebo | 3.1 |
Neuropsychiatry Inventory-Irritability (NPI-I) & Aggression domains (NPI-A): NPI is a 40-item assessment of 12 behavioral domains (NPI-I & NPI-A domains used in this study). The most problematic aspect of each domain is graded for severity (1=mild, to 3=severe) and frequency (1-4 with 4 representing highest frequency); the domain scores (0-12) are the product of severity and frequency. To best reflect treatment target intent and meet parametric statistical method criteria, the primary outcome was a composite measure of observer-rated NPI-I & -A domains transformed to a Rasch logit scale running from 0 (best) to 100 (worse) units (i.e., observer-rated NPI-I/A Rasch construct scores). Mean day-42 observer-rated NPI-I/A Rasch construct scores were compared between placebo vs. carbamazepine using ANCOVA with baseline score as covariate. (NCT00621751)
Timeframe: 42 days
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Carbamazepine | 37.7 |
| Placebo | 36.7 |
Neuropsychiatry Inventory-Irritability (NPI-I) & Aggression domains (NPI-A): NPI is a 40-item assessment of 12 behavioral domains (NPI-I & NPI-A domains used in this study). The most problematic aspect of each domain is graded for severity (1=mild, to 3=severe) and frequency (1-4 with 4 representing highest frequency); the domain scores (0-12) are the product of severity and frequency. To best reflect treatment target intent and meet parametric statistical method criteria, a composite measure of participant-rated NPI-I & -A domains transformed to a Rasch logit scale running from 0 (best) to 100 (worse) units (i.e., participant-rated NPI-I/A Rasch construct scores). Mean day-42 participant-rated NPI-I/A Rasch construct scores were compared between placebo vs. CBZ using ANCOVA with baseline score as covariate. (NCT00621751)
Timeframe: Day 42
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Carbamazepine | 37.5 |
| Placebo | 36.4 |
Proportion of participants with Minimal Clinically Important Difference (MCID) on Neuropsychiatric Inventory Irritability-Aggression Composite Measure completed by Observer. Specifically, the proportion of participants that experienced a decrease of > 1 (MCID) in the NPI-I/A Rasch construct score (i.e., participants that are considered to have meaningful reduction in irritability/aggression) from baseline to day-42 between the groups using a chi-square test. MCID was defined as 0.5 times the standard deviation of baseline scores. (NCT00621751)
Timeframe: 42-day
| Intervention | Participants (Count of Participants) |
|---|---|
| Carbamazepine | 20 |
| Placebo | 26 |
Proportion of participants with Minimal Clinically Important Difference (MCID) on Neuropsychiatric Inventory Irritability-Aggression Composite Measure completed by Participant. Specifically, the proportion of participants that experienced a decrease of > 1 (MCID) in the NPI-I/A Rasch construct score (i.e., participants that are considered to have meaningful reduction in irritability/aggression) from baseline to day-42 between the groups using a chi-square test. MCID was defined as 0.5 times the standard deviation of baseline scores. (NCT00621751)
Timeframe: Day-42
| Intervention | Participants (Count of Participants) |
|---|---|
| Carbamazepine | 21 |
| Placebo | 16 |
6 reviews available for carbamazepine and Psychomotor Agitation
| Article | Year |
|---|---|
Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation).
Topics: Administration, Oral; Aggression; Antipsychotic Agents; Carbamazepine; Humans; Oxcarbazepine; Psycho | 2018 |
[Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD)].
Topics: Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dementia; Fructose; Gabap | 2008 |
Archimedes. Question 3. Should carbamazepine be administered to manage agitation and aggressive behaviour following paediatric acquired brain injury?
Topics: Adolescent; Anticonvulsants; Brain Injuries; Carbamazepine; Child Behavior Disorders; Evidence-Based | 2010 |
[Pharmacological treatment of post-traumatic behavioural disorders].
Topics: Adrenergic beta-Antagonists; Aggression; Anti-Anxiety Agents; Antidepressive Agents; Antimanic Agent | 2003 |
Pharmacologic management of behavioral instability in medically ill pediatric patients.
Topics: Adolescent; Adrenergic alpha-Agonists; Aggression; Analgesics, Non-Narcotic; Behavior Therapy; Behav | 2004 |
Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach.
Topics: Aged; Aggression; Antipsychotic Agents; Anxiety Disorders; Behavior Therapy; Buspirone; Carbamazepin | 1996 |
7 trials available for carbamazepine and Psychomotor Agitation
| Article | Year |
|---|---|
Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Anticonvulsants; Carbamazepine; Dementia; De | 2009 |
Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamazepine; Drug Therapy, Combination; Female; Follow | 1995 |
Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study.
Topics: Aged; Aged, 80 and over; Carbamazepine; Cross-Over Studies; Dementia; Female; Homes for the Aged; Hu | 1994 |
Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Carbamazepine; Dementia; Dementia, Vascular; | 1998 |
Withdrawal from controlled carbamazepine therapy followed by further carbamazepine treatment in patients with dementia.
Topics: Aggression; Anticonvulsants; Brief Psychiatric Rating Scale; Carbamazepine; Dementia; Drug Administr | 1999 |
A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Brief Psychiatric Rating Scale; Carbamazepine; Double | 2001 |
Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Antipsychotic Agents; Carbamazepine; Cl | 1990 |
16 other studies available for carbamazepine and Psychomotor Agitation
| Article | Year |
|---|---|
Brief report: retrospective case series of oxcarbazepine for irritability/agitation symptoms in autism spectrum disorder.
Topics: Adolescent; Carbamazepine; Child; Child Development Disorders, Pervasive; Child, Preschool; Female; | 2013 |
Elevation of carbamazepine-10,11-epoxide by quetiapine.
Topics: Ataxia; Carbamazepine; Dibenzothiazepines; Drug Synergism; Female; Humans; Male; Middle Aged; Psycho | 2002 |
Carbamazepine-induced hypersensitivity syndrome, associated with human herpesvirus 6 reactivation.
Topics: Adult; Carbamazepine; Drug Hypersensitivity; Female; Herpesvirus 6, Human; Humans; Psychomotor Agita | 2004 |
Treatment of a rare psychopathological phenomenon: tactile hallucinations and the delusional other.
Topics: Aged; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Chronic Disease; Delusions; Drug Therapy | 2004 |
Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Bipolar Disorder; Carbamazepine; Central Nervous Syst | 2005 |
Auditory hallucinations after right temporal gyri resection.
Topics: Adult; Affect; Anticonvulsants; Antipsychotic Agents; Brain Injuries; Carbamazepine; Electroencephal | 2005 |
Effectiveness of carbamazepine for benzodiazepine-resistant impulsive aggression in a patient with frontal infarctions.
Topics: Aggression; Antimanic Agents; Benzodiazepines; Carbamazepine; Cerebral Infarction; Drug Resistance; | 2007 |
[A patient with disseminated lupus erythematosus caused by the use of carbamazepine (Tegretol)].
Topics: Adult; Antibodies, Antinuclear; Carbamazepine; Humans; Lupus Erythematosus, Systemic; Male; Psychomo | 1983 |
Is carbamazepine helpful in paroxysmal behavior disorders?
Topics: Adult; Carbamazepine; Drug Therapy, Combination; Epilepsy, Temporal Lobe; Humans; Male; Middle Aged; | 1983 |
Hypnogenic paroxysmal dystonia: epileptic seizure or a new syndrome?
Topics: Adult; Aged; Carbamazepine; Child; Diagnosis, Differential; Dystonia; Electroencephalography; Epilep | 1981 |
[Therapeutic use of carbamazepine for treatment of agitation and affective disorders in geriatric psychiatry patients].
Topics: Aged; Carbamazepine; Dementia; Dose-Response Relationship, Drug; Drug Administration Schedule; Femal | 1994 |
Treating the agitated Alzheimer patient.
Topics: Adrenergic beta-Antagonists; Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Buspirone; C | 1996 |
Carbamazepine in agitation and aggressive behaviour following severe closed-head injury: results of an open trial.
Topics: Adult; Aged; Aggression; Anger; Antimanic Agents; Carbamazepine; Dose-Response Relationship, Drug; F | 1999 |
Controlling agitation in patients with cognitive impairment.
Topics: Aphasia, Broca; Carbamazepine; Depressive Disorder; Drug Therapy, Combination; Epilepsy, Temporal Lo | 1991 |
Carbamazepine for aggressive agitation in demented patients during nursing care.
Topics: Aged; Aggression; Alzheimer Disease; Carbamazepine; Female; Humans; Male; Psychomotor Agitation | 1989 |
Managing behavior in mentally retarded residential populations.
Topics: Adrenergic beta-Antagonists; Aggression; Antipsychotic Agents; Carbamazepine; Humans; Institutionali | 1986 |